Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients
Authors
Keywords
-
Journal
Nature Communications
Volume 9, Issue 1, Pages -
Publisher
Springer Nature
Online
2018-04-11
DOI
10.1038/s41467-018-03867-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The prognostic value of PI3K mutational status in breast cancer: A meta-analysis
- (2018) Navid Sobhani et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Characterisation of GATA3 expression in invasive breast cancer: differences in histological subtypes and immunohistochemically defined molecular subtypes
- (2017) Tang Shaoxian et al. JOURNAL OF CLINICAL PATHOLOGY
- Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) José Baselga et al. LANCET ONCOLOGY
- High-throughput Phenotyping of Lung Cancer Somatic Mutations
- (2016) Alice H. Berger et al. CANCER CELL
- Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From BOLERO-2
- (2016) Gabriel N. Hortobagyi et al. JOURNAL OF CLINICAL ONCOLOGY
- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations
- (2015) T. Dogruluk et al. CANCER RESEARCH
- Prognostic role ofPIK3CAmutations of cell-free DNA in early-stage triple negative breast cancer
- (2015) Takashi Takeshita et al. CANCER SCIENCE
- Oncogenic mutations weaken the interactions that stabilize the p110α-p85α heterodimer in phosphatidylinositol 3-kinase α
- (2015) Ignacia Echeverria et al. FEBS Journal
- PIK3CA Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2–Targeted Therapies in Breast Cancer
- (2015) Ian J. Majewski et al. JOURNAL OF CLINICAL ONCOLOGY
- High-throughput functional genomics using CRISPR–Cas9
- (2015) Ophir Shalem et al. NATURE REVIEWS GENETICS
- Adjuvant chemotherapy for early female breast cancer: A systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline
- (2015) S. Gandhi et al. Current Oncology
- Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling
- (2014) Vandana G. Abramson et al. BREAST CANCER RESEARCH AND TREATMENT
- Naturally Occurring Neomorphic PIK3R1 Mutations Activate the MAPK Pathway, Dictating Therapeutic Response to MAPK Pathway Inhibitors
- (2014) Lydia W.T. Cheung et al. CANCER CELL
- The Double Life of p85
- (2014) Carlotta Costa et al. CANCER CELL
- CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors
- (2014) Sadhna R. Vora et al. CANCER CELL
- Mutational Analysis of PI3K/AKT Signaling Pathway in Tamoxifen Exemestane Adjuvant Multinational Pathology Study
- (2014) Vicky S. Sabine et al. JOURNAL OF CLINICAL ONCOLOGY
- Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive, First-Line Metastatic Breast Cancer
- (2014) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- PIK3CAActivating Mutations: A Discordant Role in Early Versus Advanced Hormone-Dependent Estrogen Receptor–Positive Breast Cancer?
- (2014) Ingrid A. Mayer et al. JOURNAL OF CLINICAL ONCOLOGY
- PIK3CAMutations Are Associated With Lower Rates of Pathologic Complete Response to Anti–Human Epidermal Growth Factor Receptor 2 (HER2) Therapy in Primary HER2-Overexpressing Breast Cancer
- (2014) Sibylle Loibl et al. JOURNAL OF CLINICAL ONCOLOGY
- Breast cancer in China
- (2014) Lei Fan et al. LANCET ONCOLOGY
- Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
- (2014) Dejan Juric et al. NATURE
- PI3K and cancer: lessons, challenges and opportunities
- (2014) David A. Fruman et al. NATURE REVIEWS DRUG DISCOVERY
- COSMIC: exploring the world's knowledge of somatic mutations in human cancer
- (2014) Simon A. Forbes et al. NUCLEIC ACIDS RESEARCH
- Investigating the Structure and Dynamics of the PIK3CA Wild-Type and H1047R Oncogenic Mutant
- (2014) Paraskevi Gkeka et al. PLoS Computational Biology
- Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
- (2013) Antonio C. Wolff et al. JOURNAL OF CLINICAL ONCOLOGY
- Somatic Mutation Profiling and Associations With Prognosis and Trastuzumab Benefit in Early Breast Cancer
- (2013) Sherene Loi et al. JNCI-Journal of the National Cancer Institute
- Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies
- (2013) A. B. Hanker et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells
- (2013) Ophir Shalem et al. SCIENCE
- Genetic Screens in Human Cells Using the CRISPR-Cas9 System
- (2013) Tim Wang et al. SCIENCE
- A tale of three next generation sequencing platforms: comparison of Ion torrent, pacific biosciences and illumina MiSeq sequencers
- (2012) Michael Quail et al. BMC GENOMICS
- Rap80 Protein Recruitment to DNA Double-strand Breaks Requires Binding to Both Small Ubiquitin-like Modifier (SUMO) and Ubiquitin Conjugates
- (2012) Xin Hu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- PI3K signalling: the path to discovery and understanding
- (2012) Bart Vanhaesebroeck et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- The Promise of Combining Inhibition of PI3K and PARP as Cancer Therapy
- (2012) Farah L. Rehman et al. Cancer Discovery
- Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer
- (2012) Ashish Juvekar et al. Cancer Discovery
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
- (2011) A. Goldhirsch et al. ANNALS OF ONCOLOGY
- Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
- (2011) Johanna C. Bendell et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
- (2011) S.-M. Maira et al. MOLECULAR CANCER THERAPEUTICS
- Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway–dependent and PI3K pathway–independent mechanisms
- (2011) Pixu Liu et al. NATURE MEDICINE
- A Mosaic Activating Mutation inAKT1Associated with the Proteus Syndrome
- (2011) Marjorie J. Lindhurst et al. NEW ENGLAND JOURNAL OF MEDICINE
- High Frequency of PIK3R1 and PIK3R2 Mutations in Endometrial Cancer Elucidates a Novel Mechanism for Regulation of PTEN Protein Stability
- (2011) Lydia W.T. Cheung et al. Cancer Discovery
- PIK3CA Mutations May Be Discordant between Primary and Corresponding Metastatic Disease in Breast Cancer
- (2010) J. Dupont Jensen et al. CLINICAL CANCER RESEARCH
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
- (2010) M. Elizabeth H. Hammond et al. JOURNAL OF CLINICAL ONCOLOGY
- Direct positive regulation of PTEN by the p85 subunit of phosphatidylinositol 3-kinase
- (2010) R. B. Chagpar et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Breast cancer in a transitional society over 18 years: trends and present status in Shanghai, China
- (2009) Lei Fan et al. BREAST CANCER RESEARCH AND TREATMENT
- A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer
- (2009) R L Jones et al. BRITISH JOURNAL OF CANCER
- Somatic Mutations in p85α Promote Tumorigenesis through Class IA PI3K Activation
- (2009) Bijay S. Jaiswal et al. CANCER CELL
- PIK3CA Mutation Associates with Improved Outcome in Breast Cancer
- (2009) K. Kalinsky et al. CLINICAL CANCER RESEARCH
- PIK3CA Cooperates with Other Phosphatidylinositol 3'-Kinase Pathway Mutations to Effect Oncogenic Transformation
- (2008) K. Oda et al. CANCER RESEARCH
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
- (2008) Jeffrey A Engelman et al. NATURE MEDICINE
- Helical domain and kinase domain mutations in p110 of phosphatidylinositol 3-kinase induce gain of function by different mechanisms
- (2008) L. Zhao et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Profiling Essential Genes in Human Mammary Cells by Multiplex RNAi Screening
- (2008) J. M. Silva et al. SCIENCE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started